Soma Pharmacy Blognews

Archive for December, 2009

Alnylam, Collaborators At MIT Publish New Pre-clinical Research On Lipidoid Formulations For the systemic delivery of RNAi therapeutics

CVS Caremark to provide H1N1 flu vaccinations at select locations CVS Caremark announced today that it will provide H1N1 flu vaccinations at select CVS/pharmacy locations in the States of Alabama, Illinois, Kansas, Missouri, Pennsylvania and New York as well at MinuteClinic locations in Massachusetts and Connecticut beginning Thursday, December 31.

FDA accepts NDA review for new anticonvulsant drug

Posted by: SomaNews on: 31 Dec, 2009

FDA accepts NDA review for new anticonvulsant drug The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review [...]

Biodel submits NDA to FDA for clearance to market VIAject

Posted by: SomaNews on: 31 Dec, 2009

Biodel submits NDA to FDA for clearance to market VIAject Biodel, Inc. announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for clearance to market VIAject® as a treatment for diabetes.

J&JPRD receives FDA Complete Response Letter for ceftobiprole Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin [...]

Meda expands collaboration with Etypharm for Axorid

Posted by: SomaNews on: 31 Dec, 2009

Meda expands collaboration with Etypharm for Axorid Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

Liraglutide FDA feedback expected within weeks, says Novo Nordisk Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks.

Competitive intelligence on Egypt’s pharmaceuticals and healthcare industry Research and Markets has announced the addition of the “Egypt Pharmaceuticals and Healthcare Report Q1 2010″ report to their offering.

Significant limitations in new Ginkgo biloba study published in JAMA, says ABC New research findings published this week on a standardized Ginkgo biloba extract are very limited and the public should focus on the well-documented cognitive and cardiovascular benefits of ginkgo, said the American Botanical Council (ABC), an independent nonprofit research and education organization.

CRN stands by Ginkgo biloba’s effectiveness in improving cognitive function “It is important to put this study into context and to remember that there is a large body of previously published evidence, which suggests that Ginkgo biloba may help improve cognitive impairment in older adults. There are also additional ongoing clinical trials, the results of [...]


canadian pharmacy

Categories


  • toby lee: There is some interesting data suggesting that keeping your vitamin D level optimal will prevent colds, flu and in particular H1N1 (swine Flu). The C
  • dalimmima: I think you made some good points in your post.
  • Acne Treatments Site: the H1N1 or Swine Flu Virus is very scary at first but now it is well controlled by vaccines and prevention by avoiding going into places with inciden
soma
ambien
duty free tobacco

Archives

 

December 2009
M T W T F S S
« Nov   Jan »
 123456
78910111213
14151617181920
21222324252627
28293031